Roy S. Herbst, MD, PhD, Honored by IASLC
In Partnership With:
Roy S. Herbst, MD, PhD, was honored by the International Association for the Study of Lung Cancer in recognition for his years of dedication and invaluable service to the organization and the lung cancer community.
Roy S. Herbst, MD, PhD
New Haven, Conn. — Roy S. Herbst, MD, PhD, was honored by the International Association for the Study of Lung Cancer (IASLC) in recognition for his years of dedication and invaluable service to the organization and the lung cancer community. Herbst is Deputy Director for Clinical Affairs, Chief of Medical Oncology, and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital and Assistant Dean for Translational Research at Yale School of Medicine.
“I am so honored to receive this recognition from IASLC as I am committed to further advancing lung cancer research and cancer care to help patients with this disease,” said Herbst. “I feel very proud to have helped develop novel, personalized therapies for lung cancer that have helped drive significant changes in the way the disease is treated.”
Herbst will be recognized during the IASLC “Targeted Therapies of Lung Cancer” virtual meeting on February 24th. He will deliver the faculty keynote speech during the meeting on “22 Years of Progress in the Treatment of Non-Small Cell Lung Cancer: Targeted Therapy, Immunotherapy and the IASLC Santa Monica Meeting.”
“It’s amazing the progress we have seen over the 22 years I have been involved with this meeting,” added Herbst.
About Yale Cancer Center and Smilow Cancer Hospital
Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
